GLPL.BO · BSE
GOLDLINE PHARMACEUTICAL LIMITE
₹34.9
-4.64% (-₹1.7)
Prev. close
₹36.6
Volume
9,000
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About GOLDLINE PHARMACEUTICAL LIMITE
Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty surgeons. It sells its products through distributors. The company was incorporated in 2004 and is based in Nagpur, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Amol Laxmikant Mujumdar
Headquarters
Nagpur
Employees
126
Website
goldlinepharma.inExchange
View on BSE ↗Key stats
Market cap
₹33.50 Cr
P/E ratio (TTM)
11.8
EPS (TTM)
₹2.95
Shares float
19.17 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹19.85 Cr | ₹23.57 Cr | ₹28.06 Cr | ₹31.20 Cr | |
| EBITDA | ₹2.11 Cr | ₹4.17 Cr | ₹5.96 Cr | ₹6.94 Cr |
| ₹25.66 L | ₹1.81 Cr | ₹2.83 Cr | ₹4.12 Cr | |
| Diluted EPS | — | — | — | ₹5.97 |
Total expenses (as filed), Employee benefit expense, Other expenses, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹19.39 Cr | ₹22.93 Cr | ₹26.28 Cr | — | |
| ₹10.83 Cr | ₹11.13 Cr | ₹11.03 Cr | — | |
| Stockholders' equity | ₹5.89 Cr | ₹7.87 Cr | ₹10.35 Cr | — |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2.39 Cr | ₹2.92 Cr | ₹2.32 Cr | — | |
| Investing cash flow | ₹-1.03 Cr | ₹-1.11 Cr | ₹16.23 L | — |
| ₹-1.44 Cr | ₹-1.08 Cr | ₹-2.03 Cr | — | |
| Capital expenditure | ₹-1.11 Cr | ₹-1.11 Cr | ₹-20.71 L | — |
| End cash position | ₹5.42 L | ₹78.99 L | ₹1.24 Cr | — |
Operating cash flow, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| GOLDLINE PHARMACEUTICAL LIMITE | ₹35.14 Cr | ₹36.6 | 12.4 | 3.39 | 27.4% | 1.07 | +19.1% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.